Home › Funds › PSP Research LLC › GLUE
PSP Research LLC position in GLUE
MONTE ROSA THERAPEUTICS INC · Health Care
PSP Research LLC reported holding 23,000 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$557K, representing 0.30% of its reported portfolio and ranking #11 among its reported holdings. PSP Research LLC has disclosed GLUE holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
How PSP Research LLC's GLUE position evolved
PSP Research LLC first disclosed a stake in GLUE in Q1 2026 at 28,000 shares (US$461K). The position peaked in Q2 2026 at 23,000 shares, worth US$557K. Across 2 filings, PSP Research LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 23,000 shares valued at US$557K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 28.00K | $460.60K | New |
| Q2 2026 | 23.00K | $556.60K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GLUE and 13F data
GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), Vestal Point Capital, LP (US$111.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GLUE
- NEA Management Company, LLC 7.69M sh · $186.15M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $111.86M · Q2 2026
- Vestal Point Capital, LP 4.60M sh · $111.32M · Q2 2026
- BVF INC/IL 4.46M sh · $107.95M · Q2 2026
- BAKER BROS. ADVISORS LP 4.35M sh · $105.17M · Q2 2026
- MONTANOVA CAPITAL, LLC 3.55M sh · $85.90M · Q2 2026
- Versant Venture Management, LLC 3.18M sh · $76.97M · Q2 2026
- BRAIDWELL LP 2.45M sh · $59.33M · Q2 2026
- Aisling Capital Management LP 1.56M sh · $37.65M · Q2 2026
- Bellevue Group AG 1.19M sh · $28.80M · Q2 2026
- MPM BioImpact LLC 1.16M sh · $28.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.00M sh · $24.20M · Q2 2026